Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Saturday, May 9, 2009

MS discussions on Medicare, Spasticity, bladder "dysfunction" and more

Another program from the National MS Society

Have you seen this week's Daily Minutes? Click here and go to the green box to see short clips discussing:
  • Medicare
  • Spasticity
  • Allowing axons to grow
  • Explaining bladder dysfunction

============================================

Webcast: Three Cures: Stop Repair Prevent

From the National MS Society, MS Learn Online presents:

Three Cures: Stop, Repair, Prevent
featuring John Richert, MD
focuses on:
  • Defining the cure
  • Stopping disease activity
  • Repairing the nervous system
  • Identifying the cause
Click here to view the webcasts, or
copy into your browser: http://www.nationalmssociety.org/multimedia-library/webcasts--podcasts/three-cures-stop-repair-prevent/index.aspx

If you have a pop-up blocker, you will need to disable it prior to participating in a MS Learn Online webcast.



============================================

re: Stu's Views and MS Related News - e-newsletter archiving

Effective January 1, 2009, I began archiving each of the e-newsletters that I publish each week.

For those new to our sites or those who just want to look back at things you may have missed, click this link to visit our archived google site of e-newsletters.

Have questions or comments, please either send me an email or leave comments here.

Thank you

Friday, May 8, 2009

JK Rowling is honoured to support Ryan's Bid to get every child in Scotland on Vitamin "D"

Shine On Scotland - Vitamin D for ALL -

Click here to Read of this Campaign


I am really honoured to support Ryan in his fantastic campaign to get Vitamin D for all introduced as a perventitive measure against MS. Ryan’s mother has MS as did my own mother. I only wish I had the gumption at 14 to do what Ryan is doing and get such an important issue raised at parliament. I wish him and all the other young people joining the mile march he is organising in Edinburgh the best in their endeavors. - JK Rowling

.

============================================

Positive Results of Stem Cell Transplantation to Treat Multiple Sclerosis: Study May be Key to Unlocking a Cure

Source: Red Orbit

United Spinal Association Reports Positive Results of Stem Cell Transplantation to Treat Multiple Sclerosis: Study May be Key to Unlocking a Cure

Posted on: Friday, 8 May 2009, 07:32 CDT

NEW YORK, May 8 /PRNewswire-USNewswire/ -- An article published in the Summer 2009 edition of Multiple Sclerosis Quarterly Report, a joint publication of United Spinal Association (www.UnitedSpinal.org) and the North American Research Committee on Multiple Sclerosis (NARCOMS), highlights the positive initial results of patients who have improving neurologic function after receiving a stem cell transplant, despite no longer taking any MS medications.

The results are reported in a National Institutes of Health (NIH)-sponsored study called HALT-MS to confirm whether high-dose immunosuppression followed by autologous stem cell transplantation will prevent MS attacks in patients who are not responding to available treatment options and ultimately protect against the degeneration of nerve fibers.

The article, written by George H. Kraft, MD, MS, director of the Western MS Center in Seattle, Washington, and colleagues, reveals the promising outcomes of the first three patients entered into the HALT-MS Study, including a 27-year-old woman with an 8-year history of relapsing MS who was treated with five different MS drugs, but continued to have relapses.

» Read More


.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Incidence Of PML With Tysabri In Multiple Sclerosis Lower Than Previously Thought

Source: Medical News Today
Article Date: 08 May 2009

The risk of developing progressive multifocal leukoencephalopathy (PML), a viral brain infection, in patients with multiple sclerosis (MS) taking the drug natalizumab (Tysabri) appears to be much lower - and the infection less deadly - than previously estimated, according to new postmarketing surveillance data.

Previous research found that the risk of developing PML was 1 in 1000, but new data show that the risk is closer to 1.2 per 10,000 patients, according to Carmen Bozic, MD, vice president and global head of drug safety and risk management for the maker of natalizumab, Biogen Idec, in Cambridge, Massachusetts.

Dr. Bozic delivered an updated overview of the risks and benefits of natalizumab during the American Academy of Neurology (AAN) 61st Annual Meeting.

» Read More


Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Fast Forward, LLC, Seeking Proposals in Early Stage Drug Development for MS





May 07, 2009

Proposals sought from academic institutions and seed-to-early stage companies developing novel therapeutic approaches to prevent, treat or reverse nervous system damage in multiple sclerosis

Fast Forward, LLC, a wholly-owned subsidiary of the National MS Society, and EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a commitment of $3 million in 2009 to support innovative early-stage projects directed towards the development of therapies to prevent treat, or reverse nervous system damage in MS. This is the first "Request for Proposals" (RFP) issued under the auspices of a multi-year collaboration between Fast Forward and EMD Serono to accelerate innovation and commercial development of MS therapies. Merck KGaA, the parent corporation of EMD Serono, Inc., will provide up to $19 million in total funding for the collaboration.

To read complete article please click this link that will re-direct you to the National MS Society website's article.


If not yet registered to receive the "Stu's Views and MS Related News", weekly MS related e-newsletter, then please Click Here to register.


Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

THOUSANDS OF CHILDREN EXPERIENCING WHAT MAY BE SYMPTOMS OF MULTIPLE SCLEROSIS

MS Not Just An "Adult Disease";First-Of-Its Kind Network Of Pediatric Multiple Sclerosis Centers of Excellence Established Nationwide


Story Summary:

Every hour in the United States, someone is diagnosed with multiple sclerosis, an unpredictable, often disabling disease of the central nervous system. While it’s the most common neurological condition affecting young to middle-aged adults, emerging research suggests up to 10,000 children in the U.S. are living with the condition and another 15,000 have experienced MS-like symptoms such as double vision, numbness and unexplained fatigue.

Click here to read and view videos on this topic


If not yet registered to receive the "Stu's Views and MS Related News", weekly MS related e-newsletter, then please Click Here to register.


.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Thursday, May 7, 2009

The Myelin Project




The Myelin Project knows a good story when they see it and so, they asked to promote this new News Release: http://www.myelin.org/en/rel/91/


Read more on the Myelin Project by visiting with their homepage . Information available in Spanish and English.


If not yet registered to receive the "Stu's Views and MS Related News", weekly MS related e-newsletter, then please Click Here to register.

..........................................................

Wednesday, May 6, 2009

Demystifying MRI

On May 27th, MS in BalanceSM will release a new online video:

Demystifying MRI

In just 30 minutes, you can get important facts about MRI—including how doctors may use them to help manage your relapsing MS.

This Talk MS program will feature special guests, including:

Randall Schapiro, MD
MS LifeLines® Ambassador Catherine

Click the above Demystifying link - to register

.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Multiple Sclerosis: Genetics Study to Launch Despite Challenging Times

The groundbreaking genetics study will yield clues into the causes of MS and new treatments. Still, the study and more than 40 other promising projects still need funding to move forward.
Learn more >>


Not yet receiving the "Stu's Views and MS Related News", weekly e-newsletter?
Click here to register


============================================

Vision Deteriorates Even Without Sight-Related Symptoms in Patients With Multiple Sclerosis

DG Dispatch
By Ed Susman

FORT LAUDERDALE, Fla -- May 5, 2009 -- Researchers suggest that clinicians make a point of checking patients with multiple sclerosis (MS) for diminished vision even when the patients have not experienced any vision-related symptoms such as optic neuritis.

The study was presented here on May 3 at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting.

"Our findings suggest a subclinical axonal loss in the anterior vision pathways of patients with multiple sclerosis that occurs without symptoms," said lead author Esther Bisker, MD, University of Pennsylvania, Philadelphia, Pennsylvania.

More precise studies that can reveal vision loss, such as low-contrast acuity tests, will help identify patients who may have deteriorating sight.

"Our study indicates that these tests should be performed among all patients diagnosed with multiple sclerosis, not just those with a history of vision complications," said Dr. Bisker.

Continue to read from the DG Dispatch website

============================================

For those with Multiple Sclerosis: Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing

FDA Assigns Priority Review and PDUFA Date of October 22, 2009
No Current Therapies Indicated to Improve Walking Ability in People with MS

HAWTHORNE, N.Y.--(BUSINESS WIRE)--May. 6, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Fampridine-SR New Drug Application (NDA) for filing, assigning Priority Review and a Prescription Drug User Fee Act (PDUFA) date of October 22, 2009. The PDUFA date is the target date for the FDA to complete its review of the Fampridine-SR NDA.

“I am pleased that we were able to work quickly to address the comments from the FDA and resubmit our NDA approximately three weeks from having received the Refuse to File letter on our initial NDA submission, and that the FDA accepted the filing less than two weeks later,” said Ron Cohen, M.D., Acorda Therapeutics’ President and CEO. “We are also encouraged that the FDA has elected to assign Priority Review status to the Fampridine-SR NDA.”

About Fampridine-SR

Fampridine-SR is a sustained-release tablet formulation of the investigational drug fampridine (4-aminopyridine or 4-AP). In laboratory studies, fampridine has been found to improve impulse conduction in nerve fibers in which the insulating layer, called myelin, has been damaged. Fampridine-SR is being developed by Acorda Therapeutics and manufactured by Elan Corporation plc.

Read more of this article from the Acorda website


.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

New Strategy Captures Drug Maker's Interest

New Strategy Captures Drug Maker's Interest

EMD Serono, Inc., agreed to provide Fast Forward, LLC, the Society's drug discovery subsidiary, with up to $19 million for early stage clinical development projects.

Read more >>


============================================

Tuesday, May 5, 2009

The Spanish World MS Day website has been launched

Página web del Día Mundial de la EM en Español ¡ahora disponible!
The Spanish World MS Day website has been launched with support from Spanish Arsenal FC player Cesc Fàbregas.

"La Esclerosis Múltiple necesita el apoyo de todos y en todos los lugares, para que deje de ser desconocida e incurable. Mi apoyo es incondicional, ¿contamos contigo? Cesc Fàbregas, España, futbolista, Arsenal FC.

"MS needs support from everyone everywhere, so that
more people become aware of it and we find a cure. My support is unconditional, can we count on you?"
Cesc Fàbregas, Spain, footballer Arsenal FC.


Register and show your support for the global MS movement today!

Help the global MS movement reach the target of 100,000 registrations and raise maximum awareness about the MS cause by:

* Registering yourself and/ or your organisation

* Registering your World MS Day event

* Registering your MS research
* Emailing all of your friends and colleagues and asking them to register (as an individual and/or an organisation)
source for this information from MSIF.org



.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

PV-267, A Unique Compound Intended to Redirect the Abnormal Immune Response In Multiple Sclerosis


Fast Forward, LLC and Provid Pharmaceuticals Announce Partnership for Development of PV-267, A Unique Compound Intended to Redirect the Abnormal Immune Response In Multiple Sclerosis

New York, USA and North Brunswick, NJ, May 5, 2009 – Provid Pharmaceuticals, Inc, a drug discovery company, and Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary devoted to bridging the gap between research and drug development, today announced a partnership to support Provid’s preclinical studies of PV-267. This novel compound is designed to redirect the abnormal immune response associated with multiple sclerosis (MS).

» Read More



Please return to this page to leave any comments you may have

A New Video from Wheelchair Kamikaze

View the Wheelchair Kamikaze Blog site to review his newest video

http://www.wheelchairkamikaze.com/2009/05/new-video-sunday-in-park-with-kamikaze.html

This venture takes you thru a rolling-stroll of his in Central Park, where fortunately ( on this day of taping) there weren't many hardships for navigating in a wheelchair...

More of his ventures will soon be coming and as he releases each one, you will find it on this blog...

Have you seen who (or what) MS Organization he shows at the end of each of his videos?

Check out his site (click the link found above) to learn more...


============================================

Monday, May 4, 2009

Multiple Sclerosis Relapse Rate Reduced By Nearly Half With Use of Two New Drugs

By: Drucilla Dyess
Published: Sunday, 3 May 2009

Cladribine and fingolimod, two new oral drugs, have been shown to decrease the relapse rate in people who suffer from multiple sclerosis. The drugs could become the first treatments for the disease that does not require regular injections or infusions, if they gain approval by the U.S. Food and Drug Administration (FDA).

To continue reading click this Health News article

Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================

Natalizumab May Activate Oral Herpes Viruses

By Andrew N. Wilner, MD

SEATTLE, Wash -- May 3, 2009 -- Oral herpes virus (HSV-1) eruptions were 3 times more likely in patients with multiple sclerosis who were taking natalizumab than in multiple sclerosis patients on no therapy, according to research presented here at the American Academy of Neurology (AAN) 61st Annual Meeting.

Nicoline Schiess, MD, Johns Hopkins Medical Center, Baltimore, Maryland, and colleagues evaluated the activity of various herpes viruses in 34 patients with multiple sclerosis taking natalizumab and 34 age- and gender-matched healthy controls, as well as 20 patients with multiple sclerosis on no therapy and 20 patients with multiple sclerosis on interferon therapy. The results of their evaluation were presented here on April 28.

Continue reading this story from the doctors' guide

.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================